Medicortex Finland Oy Announces Issuance of a Patent in the United States
TURKU, Finland. Medicortex Finland Oy, a biopharmaceutical company focusing on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering company’s diagnostic kit and innovative brain injury biomarker.
“This is our biggest achievement by now, we are extremely pleased with the development of the patent portfolio” said Dr. Harel Adrian, Chief Executive Officer of Medicortex. “This new issuance continues to expand the intellectual property portfolio covering methods of using certain biomarkers for detection of concussion. The issuance of this patent is another step in the development of a robust patent portfolio relating to new strategy to help identify and treat mild TBI” Dr. Harel continued with great pleasure.
Medicortex is currently developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury from urine or saliva. The kit is based on specific biomarkers that the company has discovered from body fluids following brain injury. Such a rapid kit will satisfy the urgent need to improve the detection of brain injury in mild cases especially – which are known to be potentially morbid but difficult to diagnose with the contemporary means. The issued patent covers the core technology and method for detecting novel glycan-based biomarkers which are indicative of traumatic brain injury.
The issued US patent No. 10,739,335 “Prognostic and Diagnostic Glycan-Based Biomarkers of Brain Damage” is the second grant in the patent family where relative national patents were previously issued by the European Patent Office (EPO). Patenting of disease biomarkers and related diagnostics is becoming very tough in the USA, so the allowance of the current patent is a great achievement in that sense.
Medicortex’ patent portfolio encompasses diagnostics of TBI biomarkers as well as relative drug candidates developed by the company. The comprehensive patent coverage secures exclusivity to develop the products and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.
Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
About Medicortex Finland Oy
Itäinen Pitkäkatu 4 B
Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence and severity of a head injury. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Medicortex was established by an Israeli neurobiologists Adrian Harel (PhD, MBA) in 2014, and the company is based in Turku, Finland.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Medicortex assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Subscribe to releases from Medicortex Finland Oy
Subscribe to all the latest releases from Medicortex Finland Oy by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Medicortex Finland Oy
Medicortex Finland Oy Announces Issuance of a Patent in Canada3.8.2021 08:25:25 EEST | Press release
TURKU, Finland. Medicortex Finland Oy, a biopharmaceutical company focusing on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that company’s core patent covering the diagnostic kit and innovative biomarker was granted in Canada.
Business Finland myönsi rahoitusta Medicortexille4.3.2021 14:58:53 EET | Tiedote
Medicortex Finland Oy, turkulainen aivovammojen diagnostiikkaan ja lääkekehitykseen erikoistunut yritys, on saanut rahoitusta Business Finlandilta. Rahoituksen avulla yritys voi nopeuttaa tapaturmaisten aivovamman ja aivotärähdyksen havaitsemiseen käytettävän pikatestin kehitystä.
Medicortex Finland Oy Announces the Advancement in Clinical Trial for Detection of Mild Traumatic Brain Injury in Children31.8.2020 15:43:39 EEST | Press release
TURKU, Finland. Medicortex Finland Oy announces achievement of the halfway in the clinical trial for detection of mild traumatic brain injury (TBI) and concussion in children and adolescents. Company's third clinical trial is being conducted at Satasairaala hospital in Finland. About 50% of the target number of head injury patients and healthy controls have already been enrolled in the study which started in March this year.
Medicortex Finland Oy Announces the Progression of Clinical Trial for Detection of Mild Traumatic Brain Injury in Children9.6.2020 12:15:42 EEST | Press release
TURKU, Finland. Medicortex Finland Oy announces the progression of clinical trial for detection of mild Traumatic Brain Injury (TBI) and concussion. Company’s third clinical trial is focusing on children and adolescents, and the recruitment of patients is taking place at Satasairaala hospital in Finland. The first patients with head injury and the first healthy controls have been enrolled in the study.
Medicortex Finland Oy:lle ELY-rahoitusta28.5.2020 14:59:30 EEST | Tiedote
Turku, 28.05.2020. Medicortex Finland Oy on saanut ELY-keskuksen myöntämää kehittämisavustusta aivovammatestin kehittämiseen. Saatu rahoitus mahdollistaa pikatestin kehitystyön jatkamisen ja viemisen seuraavaan vaiheeseen.
Medicortex Finland Oy:lle tutkimusrahoitusta Yhdysvaltain Puolustusministeriöltä3.7.2019 14:00:00 EEST | Tiedote
Turku, 03.07.2019. Medicortex Finland Oy:lle on myönnetty Yhdysvaltain puolustusministeriön 1,1 miljoonan dollarin tutkimusrahoitus. Rahoituksen avulla yhtiö jatkaa ProbTBITM -aivovammatestin kliinistä kehitystyötä. Tämä vahvasti kilpailtu rahoitus on samalla myös tunnustus Medicortexin teknologian ja tuotteen kyvylle vastata kasvavaan tarpeeseen määrittää tapaturmainen aivovamma tai aivotärähdys nopeasti ja luotettavasti.